Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies. 

Eureka Therapeutics, headquartered in the San Francisco Bay Area, leverages its proprietary ARTEMIS^® cell receptor and E‑ALPHA^® antibody discovery platforms to drive innovation in safer, more effective T‑cell therapies. Through this collaboration, the two parties aim to accelerate Eureka's global clinical development by capitalizing on Porton Advanced's world-class cell and gene therapy manufacturing capabilities at their GMP sites.

Oliver Ju, Chairman of Porton Advanced, commented: "We are delighted to establish our partnership with Eureka. The seamless completion of the initial part of our collaboration program underscores our team's operational excellence and commitment to quality. Our continued collaboration will leverage our flexible models and state‑of‑the‑art manufacturing capabilities to expedite the development of groundbreaking advanced therapies."

Dr. Cheng Liu, Founder and CEO of Eureka Therapeutics, stated: "We are confident that through close collaboration with Porton Advanced, Eureka is well-positioned to accelerate our key pipeline programs, supported by Porton's robust and reliable manufacturing capabilities."